Immunoglobulins TRIZ Cases

An interpenetrating polymer-silica network boosts fluorescence brightness and photostability while preventing aggregation in biological buffers.

Quinazoline-2,4-diamine derivatives inhibit EHMT2 to restore tumor-suppressor gene expression and help suppress cancer cell growth.

Double-antibody HBcAg detection targets conserved epitopes to reduce false negatives and enable rapid HBV replication quantification.

Payload-binding agents sequester free ADC payload to curb off-target toxicity and support higher anti-tumor dosing.

Monoclonal anti-LAM binding plus silver signal amplification improves tuberculosis immunochromatography sensitivity and specificity.

Uses flanking-sequence peptide libraries to find affinity reagents that bind a target epitope consistently across varied sequence contexts.

Anti-B7H3 ADCs use tumor-targeting antibodies and cleavable linkers to deliver KSP inhibitors at lower doses while limiting normal tissue damage.

Recombinant anti-IgG nanobodies replace polyclonal secondary antibodies while preserving strong detection, improving tissue penetration, and enabling precise labeling.

Matching synonymous codon frequencies to host-cell usage improves recombinant polypeptide expression while avoiding uniform sequence design.

Site-specific HER2 antibody-TLR agonist conjugates localize tumor immune stimulation to reduce cytokine release syndrome.

Polymer-linked ADC nanoaggregates improve tissue specificity and cytotoxicity against both antigen-positive and antigen-negative tumor cells.

Pre-designed nucleic acid libraries enrich glycan-binding antibody variants, balancing sequence diversity with high affinity and specificity.

Candidate sequence matching and consensus assembly resolve repetitive multivalent ISV reads in minutes while preserving sequencing accuracy.

A hydrophilic, cleavable ADC linker reduces mouse plasma instability, lowers aggregation, and extends in vivo residence time.

Labeled anti-BCMA CAR antibodies enable precise flow cytometry and related assays to quantify CAR expression and persistence on T cells.

Novel ADC linkers improve selective cancer cell internalization and payload release while reducing non-specific binding and systemic toxicity.

Modular antibody, linker, and drug design improves payload specificity to cancer cells while preserving ADC flexibility across targets.

A GGFL linker stays stable in circulation but is cleaved by cathepsin L in tumors, enabling selective cytotoxic release with lower off-target toxicity.

Targeted RMCE in CHO cells builds bispecific antibody libraries with one antibody type per cell, reducing mixed expression and improving screening accuracy.

Engineered CEACAM5-targeting ADCs use optimized CDRs and linkers to kill tumor cells while limiting cross-reactivity and off-target effects.

Selective VHH framework retention and CDR mutations preserve tag-binding affinity while lowering immunogenicity and enabling SpA-based production.

Specialized linker structures keep high-DAR ligand-payload conjugates stable, improving therapeutic index and efficacy for targeted treatment.

Using mouse chromosome 10 or 16 with natural centromere and telomere features improves vector retention, progeny transmission, and antibody expression.

Water-soluble linker chemistry helps camptothecin ADC conjugates avoid aggregation, raise DAR, and reduce systemic toxicity.

Masked PBD dimers linked through antibody glycans improve ADC tolerability by enabling enzyme-triggered payload release in tumors.

Combining two payloads with different mechanisms lets an ADC balance stable circulation, tumor-site release, and resistance-resistant killing.

A transgenic mouse with a human Vκ-mouse Jκ common light chain improves bispecific antibody yield by enabling consistent in vivo heavy-chain pairing.

By linking light-chain variable domains to heavy-chain constant regions, this approach broadens epitope recognition and supports higher-affinity binding.

Addressable nucleic acid sites control epitope valency and spacing in 3D, reducing heterogeneous immune-complex aggregates.

Selective disulfide reduction exposes antibody cysteines for uniform drug loading and more homogeneous, stable ADCs.

Transition metal ions and reductants selectively reduce and re-oxidize antibody disulfides for homogeneous ADC loading and intact Fc function.

TLR7/8 agonists can cause systemic side effects; this AIAC composition targets HER2-positive tumors to localize immune activation.

Random lysine or hinge-cysteine conjugation creates mixed DARs; engineered cysteine 93 enables stable, site-specific ADC assembly.

Natural centromeres, telomeres, and low-gene long-arm fragments help retain mouse artificial chromosomes in rodent cells and tissues.

Engineered Man3 glycans connect target-binding proteins with mannose receptors to drive endocytosis and lysosomal degradation.

Large ADCs can penetrate solid tumors poorly, while smaller fragments clear quickly; FcRn-enabled HER2 Fcab conjugates address both limits.

Chemically induced dimerization often lacks ligand sensitivity; this case uses CDR-specific antibodies that dimerize only when cannabidiol is present.

Segmented micro-wells retain single cells for parallel culture and fluorescence screening of high-producing recombinant protein strains.

LC-MS analysis calculates site-specific and total glycosylation indices, supporting process control and biosimilarity assessment.

A non-binding protein scaffold and peptide linker deliver therapeutic or diagnostic moieties through disease-selective macropinocytosis.

This case uses constrained HVR-H1, HVR-H2, and HVR-H3 variation to broaden antibody recognition without making screening impractical.

MDCK cells expressing human FcRn and B2M model transcytosis to improve human PK prediction without animal studies.

Engineered CD16a-binding agents target high- and low-affinity receptors to support immune-cell recruitment and therapeutic efficacy.

Specific Fc substitutions increase FcγRIIa over FcγRIIb binding while maintaining pH-dependent FcRn binding and longer half-life.

Early cell viability measurements adjust culture duration to balance recombinant polypeptide titer with sialic acid specifications.

DNA scaffolds display target-specific peptides for high-affinity protein blocking with light-controlled, reversible binding.

Targeted R298K and N10 substitutions improve CHO selection stringency and stability without disrupting substrate binding.

Marker-assisted selection accelerates homozygosity in tomato line 1T247, resolving the trade-off between genetic stability and breeding time.

PH12FT maize variety combines disease resistance and yield through controlled genetic crosses, resolving environmental adaptability trade-offs.

Hybrid corn variety CH286440 utilizes cytoplasmic male sterility to control pollination and ensure genetic uniformity.

CV016780 inbred corn plant resolves genetic non-uniformity through self-pollination segmentation, ensuring predictable hybrid performance.

Soybean variety S110159 delivers stable yield and disease resistance through controlled breeding methods.